Download PDF
Thromb Haemost 1960; 4(02): 276-282
DOI: 10.1055/s-0038-1654506
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Variation in the Reducing Power of Plasma and Serum in Hypoprothrombinemia and Hemophilia

L. A Pálos
1   2nd Medical Clinic (Director: Prof. I. Haynal) of the University of Budapest
› Author Affiliations
Further Information

Publication History

Publication Date:
17 June 2018 (online)

    Permissions and Reprints

Summary

Normal plasma (or serum) reduces methylene blue into its colourless leukomethylene blue form as a result of heating. If the prothrombin complex (= prothrombin + factors VII, IX and X) of the plasma is decreased by dicoumarin treatment or removed by adsorption, the reducing time of methylene blue will be shortened significantly. The plasma (serum) of hemophilic patients (type A), similarly to hypoprothrombinemia, reduced methylene blue more rapidly than the plasma (serum) of normal individuals. Our examinations indicated a competition for H+, between the prothrombin complex and methylene blue and between the antihemophilic globulin and methylene blue. If prothrombin complex or antihemophilic globulin are absent from the plasma, more H+ will be available for the methylene blue resulting in its more rapid reduction into the colourless form of leuko-methylene blue.

The competition could be ėxplained that both prothrombin complex and antihemophilic globulin contain free -S-S bonds acting as an oxidizing—reducing system.

 

  • References

  • (1) Savignac R. J, Gant J. C, Sizer I. W. Reducing properties of serum from malignant and nonmalignant patients and from normal individuals. Research Conference on Cancer. 241 1944
    PubMedGoogle Scholar
  • (2) Black M. M. Changes in reducing power of serum or plasma of patients with malignant neoplastic disease. Cancer Research 7: 321 1947;
    PubMedGoogle Scholar
  • 2a Black M. M. Sulfhydryl reduction of methylene blue with reference to alterations in malignant neoplastic disease. Cancer Research 7: 592 1947;
    PubMedGoogle Scholar
  • (3) Warner E. D, Brinkhous K. M, Smith H. P. Amer. J. Biol. 144: 667 1936; Quantitativ study on blood clotting: prothrombin fluctuations under experimental conditions..
    PubMedGoogle Scholar
  • (4) Owren P. A. The coagulation of blood. Investigations on a new clotting factor. Acta med. scand. Suppl. 194 1947;
    PubMedGoogle Scholar
  • (5) Cohn E. J, Strong L. E, Hughes W. L, Mulford D. J, Ashworth J. N, Melin M, Taylor H. L. Preparations and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Amer. chem. Soc. 68: 459 1946;
    CrossrefPubMedGoogle Scholar
  • (6) Cit. Deutsch E. Blutgerinnungsfaktoren. 167 F. Deuticke; Wien: 1955
    Google Scholar
  • (7) Pálos L. A. Sauerstoffhaushalt und Thrombininaktivierung. Schweiz, med. Wschr. 73: 112 1948;
    PubMedGoogle Scholar
  • 7a Pálos L. A. Respiration and blood-coagulation. Acta med. scand. 134: 221 1949;
    PubMedGoogle Scholar
  • 7b Pálos L. A. Atmung, Kreislauf und Blutgerinnung als funktionelle Einheit. I. internationale Tagung über Thrombose und Embolie, Basel. 1954: 54 Schwabe; Basel:
    Google Scholar
  • 7c Pálos L. A. Neue Angaben über den Zusammenhang zwischen Atmung und Blutgerinnung. Transactions of the 6th Congr. of the Eur. Soc. of Hemat. 440 Copenhagen: 1957
    Google Scholar